$911.98
0.62%
Nasdaq, Nov 28, 07:00 pm CET
ISIN
US04016X1019
Symbol
ARGX

argenx SE ADR Stock price

$911.98
+75.59 9.04% 1M
+335.74 58.26% 6M
+296.98 48.29% YTD
+297.39 48.39% 1Y
+532.98 140.63% 3Y
+625.16 217.96% 5Y
+888.98 3,865.13% 10Y
+888.98 3,865.13% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
-5.65 0.62%
ISIN
US04016X1019
Symbol
ARGX
Industry

New AI Insights on argenx SE ADR Insights AI Insights on argenx SE ADR

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$56.5b
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
39.5 | 54.5
P/S
15.7 | 13.5
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
88.7%
Return on Equity
15.2%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$3.6b | $4.2b
EBITDA
- | $1.0b
EBIT
$800.4m | $1.0b
Net Income
$1.5b | -
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
64.7% | 90.9%
EBITDA
- | 22,503.4%
EBIT
334.9% | 7,309.1%
Net Income
1,449.8% | -
Free Cash Flow
-
Margin (TTM | estimate)
Gross
89.6%
EBITDA
- | 25.0%
EBIT
22.2%
Net
42.5% | -
Free Cash Flow
-
More
EPS
$23.1
FCF per Share
-
Short interest
3.3%
Employees
2k
Rev per Employee
$1.4m
Show more

Is argenx SE ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

argenx SE ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a argenx SE ADR forecast:

23x Buy
92%
2x Hold
8%

Analyst Opinions

25 Analysts have issued a argenx SE ADR forecast:

Buy
92%
Hold
8%

Financial data from argenx SE ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
3,605 3,605
65% 65%
100%
- Direct Costs 374 374
63% 63%
10%
3,231 3,231
528% 528%
90%
- Selling and Administrative Expenses 1,223 1,223
5% 5%
34%
- Research and Development Expense 1,290 1,290
447% 447%
36%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 800 800
335% 335%
22%
Net Profit 1,533 1,533
1,450% 1,450%
43%

In millions USD.

Don't miss a Thing! We will send you all news about argenx SE ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

argenx SE ADR Stock News

Positive
Seeking Alpha
4 days ago
argenx continues to outperform expectations, driven by Vyvgart's strong commercial momentum and impressive growth in CIDP and gMG markets. Vyvgart is on track to deliver more than $4.1 billion in net sales in 2025, and there are five late-stage readouts in 2025 that could further improve the long-term outlook. Profitability and robust cash generation add business development as another avenue f...
Neutral
Seeking Alpha
12 days ago
This quarter, we re-established a position in Arista Networks, a leading provider of high-performance networking solutions for data centers, cloud providers, and enterprises. We initiated a starter position in Synopsys after shares sold off following the company's third quarter earnings report and our in-person meeting with management. We exited our CyberArk Software Ltd. position after its acq...
Neutral
Seeking Alpha
13 days ago
The S&P 1500 Health Care Index advanced 4.0% in the third quarter, underperforming the S&P 500, which gained 8.1%. Stock selection within biotechnology and health care providers & services, along with an overweight to biotechnology and an underweight to medtech added the most value relative to the Index. Security selection within medtech, life sciences tools & services, and pharmaceuticals detr...
More argenx SE ADR News

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.

Head office Netherlands
CEO Tim Hauwermeiren
Employees 1,599
Founded 2008
Website www.argenx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today